Preservation of Fertility in the Cancer Patient

Posted 3/17/2005
Tommaso Falcone , MD 
 

Treatment of malignancies in young women has improved significantly to
the extent that patients are increasingly consulting physicians before
undergoing cancer treatment to discuss what can be done to preserve
their fertility. Proper counseling of these patients requires a
detailed knowledge of the impact of the specific chemotherapeutic
agent or radiotherapy dose on fertility. Some agents may have little
or no impact and, therefore, no specific intervention is required
other than counseling. Others, such as alkylating agents, have a
profound effect.

Several options are available to a young woman who is at high risk for
damage to her ovaries by cancer treatment. The most commonly used drug
for preservation of fertility in the cancer patient is a
gonadotropin-releasing hormone agonist (GnRHa). The concept is to
induce hypogonadism before starting chemotherapy, although the
efficacy of the therapy is controversial. GnRHa is not used for
protection from radiotherapy-induced damage but may be useful if
chemotherapy is used with the radiotherapy, which is often the case.
The other forms of treatment to preserve fertility require assisted
reproductive technologies, such as oocyte or embryo freezing. These
procedures require some time to stimulate the ovary to produce
oocytes. This time may not be available. If there is no partner,
oocytes can be cryopreserved, although the results are not as good as
those achieved with embryo cryopreservation. Another option is to
remove ovarian tissue, cryopreserve it, and then transplant it back
into the patient when the therapy is complete and the patient is ready
to have children. However, only 1 patient has had a successful
pregnancy with this procedure, and it is still considered
experimental.

One of the oldest methods of preserving fertility is ovarian
transposition, the subject of the case report by Farber and
colleagues. It has been reported for decades with mixed results. The
advantage of laparoscopic access is that it allows a quick recovery
that permits initiation of radiotherapy sooner than laparotomy. The
technique described by Farber and colleagues is that of transposition
to the paracolic gutters, which has been previously achieved with
laparotomy. Fortunately, the 5-fluorouracil used in this case does not
carry a high risk of gonadal toxicity. The patient's menstrual cycle
resumed normally with luteal phase progesterone compatible with
ovulation. The proper time to measure FSH and estradiol to assess
ovarian reserve is in the early part of the cycle, usually Day 3, and
not in the luteal phase.

Although the patient did not attempt pregnancy in this case,
successful pregnancies have been reported with laparotomy and
laparoscopy. The report by Farber and colleagues highlights one option
among several that are available to women with malignancies who are
seeking to preserve their fertility.

Related Links
Clinical Articles

http://www.medscape.com/viewarticle/499240?src=mp





------------------------ Yahoo! Groups Sponsor --------------------~--> 
Dying to be thin?
Anorexia. Narrated by Julianne Moore .
http://us.click.yahoo.com/7visLB/gsnJAA/xGEGAA/8zSolB/TM
--------------------------------------------------------------------~-> 

New! Sign up for local CML support group meetings in your local community at 
http://cml.meetup.com

Apply for Commercial Real Estate loans online and submit your deal to dozens of 
hungry lenders in just minutes. Loan programs for all types of business and 
commercial real estate. Apply anytime at http://realestatezoo.com 

CML (Chronic Myelogenous Leukemia Support List) 
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com 

Post Message: [email protected] 
Subscribe:  [EMAIL PROTECTED] 
Unsubscribe:  [EMAIL PROTECTED] 
Change To No Mail/Web: [EMAIL PROTECTED] 
Change To Digest: [EMAIL PROTECTED] 
Change To Email: [EMAIL PROTECTED] 
List Help: [EMAIL PROTECTED]  
CML Group Web Site http://groups.yahoo.com/group/CML 
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
    http://groups.yahoo.com/group/CML/

<*> To unsubscribe from this group, send an email to:
    [EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
    http://docs.yahoo.com/info/terms/
 



Reply via email to